Genetic variation in IL-16 miRNA target site and time to prostate cancer diagnosis in African-American men

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 4, 2013, Pages 308-314

  Hughes, L ^a   Ruth, K ^a   Rebbeck, T R ^b   Giri, V N ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

African American; Genetic variation; MicroRNA; Prostatic neoplasms; Screening

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; INTERLEUKIN 16; INTERLEUKIN 18; MICRORNA;

ADULT; AFRICAN AMERICAN; AGED; ALOX15 GENE; ARTICLE; BINDING SITE; CANCER RISK; CANCER SCREENING; CAUCASIAN; CLINICAL EVALUATION; CONTROLLED STUDY; ETHNICITY; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; IL 16 GENE; IL 18 GENE; MALE; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PYROSEQUENCING; RAF1 GENE; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AFRICAN AMERICANS; AGED; BINDING SITES; FOLLOW-UP STUDIES; GENETIC VARIATION; HUMANS; INTERLEUKIN-16; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS; RNA INTERFERENCE;

EID: 84887614107     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.36     Document Type: Article

References (34)

1. American Cancer Society. Cancer Facts & Figures 2013. American Cancer Society: Atlanta, GA, USA, 2013.
2. Bratt O, Damber JE, Emanuelsson M, Gronberg H. Hereditary prostate cancer: clinical characteristics and survival. J Urol 2002; 167: 2423-2426.
3. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89: 3367-3371.
4. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol 1993; 150: 797-802.
5. Powell IJ. Epidemiology and pathophysiology of prostate cancer in African-American men. J Urol 2007; 177: 444-449.
6. Bigler SA, Pound CR, Zhou X. A retrospective study on pathologic features and racial disparities in prostate cancer. Prostate Cancer 2011; 2011: 239460.
7. Bratt O, Kristoffersson U, Olsson H, Lundgren R. Clinical course of early onset prostate cancer with special reference to family history as a prognostic factor. Eur Urol 1998; 34: 19-24.
8. McNaughton-Collins MF, Barry MJ. One man at a time-resolving the PSA controversy. N Engl J Med 2011; 365: 1951-1953.
9. Gomella LG, Liu XS, Trabulsi EJ, Kelly WK, Myers R, Showalter T et al. Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol 2011; 18: 5875-5883.
10. American Cancer Society guideline for the Early Detection of Prostate Cancer: Update 2012Available from http://www.cancer.org/Healthy/FindCancerEarly/ CancerScreeningGuidelines/american-cancer-society-guidelines-for-the- earlydetection-of-cancer (accessed 20 August 2012).
11. Basch E, Oliver TK, Vickers A, Thompson I, Kantoff P, Parnes H et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. J Clin Oncol 2012; 30: 3020-3025.
12. Early Detection of Prostate Cancer. AUA Guideline 2013. Available from http://www.auanet.org/education/guidelines/prostate-cancer-detection.cfm (accessed 13 May 2013).
13. Jansson MD, Lund AH. MicroRNA and cancer. Mol Oncol 2012; 6: 590-610.
14. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007; 67: 6130-6135.
15. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518.
16. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008; 3: e3148.
17. Kelavkar UP, Parwani AV, Shappell SB, Martin WD. Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model. Neoplasia (New York, NY 2006; 8: 510-522.
18. Liu Y, Lin N, Huang L, Xu Q, Pang G. Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol 2007; 26: 613-618.
19. Thomas G, Jacobs KB, Yeager M, Kraft P, Wacholder S, Orr N et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-315.
20. Mukherjee R, Bartlett JM, Krishna NS, Underwood MA, Edwards J. Raf-1 expression may influence progression to androgen insensitive prostate cancer. Prostate 2005; 64: 101-107.
21. Comperat E, Roupret M, Drouin SJ, Camparo P, Bitker MO, Houlgatte A et al. Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. Prostate 2010; 70: 1622-1627.
22. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
23. Chen K, Song F, Calin GA, Wei Q, Hao X, Zhang W. Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. Carcinogenesis 2008; 29: 1306-1311.
24. Batai K, Shah E, Murphy AB, Newsome J, Ruden M, Ahaghotu C et al. Finemapping of IL16 gene and prostate cancer risk in African Americans. Cancer Epidemiol Biomarkers Prev 2012; 21: 2059-2068.
25. Tse BW, Russell PJ, Lochner M, Forster I, Power CA. IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. PLoS One 2011; 6: e24241.
26. Tang S, Bhatia B, Maldonado CJ, Yang P, Newman RA, Liu J et al. Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells. J Biol Chem 2002; 277: 16189-16201.
27. Landi D, Gemignani F, Barale R, Landi S. A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. DNA Cell Biol 2008; 27: 35-43.
28. Giri VN, Beebe-Dimmer J, Buyyounouski M, Konski A, Feigenberg SJ, Uzzo RG et al. Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol 2007; 178: 1920-1924.
29. Eskew LA, Woodruff RD, Bare RL, McCullough DL. Prostate cancer diagnosed by the 5 region biopsy method is significant disease. J Urol 1998; 160(Part 1): 794-796.
30. Laan M, Qvarfordt I, Riise GC, Andersson BA, Larsson S, Linden A. Increased levels of interleukin-16 in the airways of tobacco smokers: relationship with peripheral blood T lymphocytes. Thorax 1999; 54: 911-916.
31. Rovina N, Dima E, Gerassimou C, Kollintza A, Gratziou C, Roussos C. IL-18 in induced sputum and airway hyperresponsiveness in mild asthmatics: effect of smoking. Respir Med 2009; 103: 1919-1925.
32. Opstad TB, Pettersen AA, Arnesen H, Seljeflot I. Circulating levels of IL-18 are significantly influenced by the IL-18 183 A/G polymorphism in coronary artery disease patients with diabetes type 2 and the metabolic syndrome: an observational study. Cardiovasc Diabetol 2011; 10: 110.
33. Blaesild P, Grandfeldt J. Statistics with Applications in Biology and Geology. 1st edn. Chapman & Hall/CRC Press: New York, NY and Englewood Cliffs, NJ, 2002.
34. Fang Z, Rajewsky N. The impact of miRNA target sites in coding sequences and in 3'UTRs. PLoS One 2011; 6: e18067.